F. Hoffmann-La Roche AG
Pharmaceuticals and DiagnosticsFounded 1896- Updated June 2025
Reviewed by Swet Parvadiya
Last reviewed: June 2025
CorpDigest
F. Hoffmann-La Roche AG
Company History
Founded 1896 in Basel, Switzerland
Last reviewed: 2025-06-08 · By Swet Parvadiya
Fritz Hoffmann-La Roche established the company in Basel in 1896 with a specific thesis: that standardized pharmaceutical manufacturing could replace the variable-quality preparations dispensed by individual pharmacists. The idea that a drug should have predictable potency and consistent composition was not universally accepted in 1896 — it was a business model and a public health argument simultaneously. The company's early success with products like Thiocol for tuberculosis and Digalen for heart conditions established the brand as a provider of reliable, measurable medicines.
The Basel location was not accidental. Switzerland's political neutrality, its proximity to German pharmaceutical chemistry, and its banking secrecy made it the natural home for pharmaceutical manufacturers who needed to operate across European borders without entanglement in nationalist trade barriers. Roche shared the Baselarea with Novartis, Ciba, and Sandoz — a pharmaceutical concentration that made Switzerland the per-capita pharmaceutical R&D leader in the world.
The twentieth century at Roche was defined by the discovery of Valium and Librium in the 1960s, which became the bestselling pharmaceuticals in the world and generated the cash flows that funded the company's subsequent expansion into diagnostics and oncology. The acquisition of a majority stake in Genentech, the San Francisco biotechnology pioneer, and eventual full acquisition in 2009 gave Roche access to monoclonal antibody technology that became the foundation for its oncology portfolio — Herceptin, Avastin, and MabThera — the drugs that defined the company's revenue profile for a decade.
F. Hoffmann-La Roche & Co. was founded on October 1, 1896 in Basel, Switzerland by Fritz Hoffmann-La Roche, then 28 years old, together with a partner who departed shortly after. Hoffmann came from a Basel commercial family and married Adele La Roche, adding her surname to his own as was the local custom; the combined name became the company's. The original business focused on the industrial production of standardized pharmaceutical preparations at a time when most drugs were still compounded by individual pharmacists, a model that was beginning to be displaced by branded, large-scale products with consistent dosing. Roche's first commercial success was a cough preparation called Sirolin, launched in 1898, followed by a sleeping pill called Pantopon and several thyroid products. By 1914 Roche had subsidiaries in Milan, New York, Paris, London, St. Petersburg, and Yokohama, making it one of the first multinational pharmaceutical companies. The First World War cut off the German and Austrian markets, and the Russian Revolution wiped out the St. Petersburg operation, but Roche survived through US and South American expansion. Fritz Hoffmann-La Roche died in 1920 at age 51, leaving the company in the hands of his family and management team.
The Hoffmann, Oeri, and Duschmalé families, all descendants of founder Fritz Hoffmann-La Roche and his daughter Maja Hoffmann-Oeri, have maintained continuous voting control of Roche Holding AG since the early twentieth century through a pooled shareholder agreement. The family pool holds the majority of Roche's voting shares (the registered bearer shares), giving them roughly 50 percent of the voting power despite owning a much smaller share of total economic value (approximately 9 to 11 percent depending on classification, when accounting for the non-voting profit-participation shares known as Genussscheine that trade in much larger volume on the SIX Swiss Exchange). The pool agreement requires unanimity for transfers outside the family and obligates members to vote their shares together at the annual general meeting. This structure has been remarkably durable: it has allowed Roche to maintain a multi-decade horizon on R&D investment, to acquire Genentech in stages over nineteen years, and to avoid the kind of activist pressure or short-term financial engineering that has reshaped other large pharma companies. Andre Hoffmann, a great-grandson of the founder, serves as Vice Chairman of the Board, embedding the family directly in governance.
After Fritz Hoffmann-La Roche's death in 1920, Roche grew through a series of scientific bets that defined the modern company. In the 1930s the company industrialized vitamin synthesis under chemist Tadeus Reichstein, who later won a Nobel Prize, and became the world's leading vitamin manufacturer (a business it would eventually divest to DSM in 2003 for CHF 3.4 billion). In the 1950s and 1960s Roche developed the benzodiazepines Librium (chlordiazepoxide, 1960) and Valium (diazepam, 1963), which became the most prescribed drugs in the United States during the 1970s and generated the cash that funded the company's later transformation. In 1990 Roche acquired a 60 percent stake in the South San Francisco biotechnology company Genentech for $2.1 billion, the first major pharma-biotech alliance and the deal that ultimately reshaped Roche's identity. Through the 1990s and 2000s the company exited cosmetics (Givaudan, spun off in 2000), fragrances and flavors, and vitamins, refocusing on prescription pharmaceuticals and diagnostics. The acquisition of Boehringer Mannheim in 1998 for $11 billion gave Roche its leading position in diagnostics. By the end of the 1990s the company had assumed the dual-business shape it retains today.
Roche operates two reporting divisions, Pharmaceuticals and Diagnostics, which together generated approximately CHF 60 billion in revenue in 2024. The Pharmaceuticals Division contributes roughly three-quarters of revenue and includes prescription drugs across oncology, neuroscience, immunology, hematology, and ophthalmology, with brands such as Ocrevus (multiple sclerosis), Hemlibra (hemophilia A), Vabysmo (age-related macular degeneration and diabetic macular edema), Phesgo (breast cancer), and Tecentriq (immuno-oncology). The Diagnostics Division contributes roughly one-quarter of revenue and is the world's largest in vitro diagnostics business by sales, encompassing the cobas family of laboratory analyzers, molecular and tissue diagnostics, point-of-care testing, and the diabetes-care business sold to French private equity in 2022. The two divisions are operationally separate but strategically aligned around what Roche calls personalized healthcare: diagnostics generates the data and biomarkers that guide the use of targeted therapies developed by Pharma. The HER2 test for breast cancer paired with Herceptin is the canonical example. The arrangement has supported a multi-decade case for keeping the two divisions inside one company despite occasional analyst pressure to split.
In November 2022 Roche announced that its Phase 3 GRADUATE I and GRADUATE II trials of gantenerumab, an anti-amyloid antibody for early Alzheimer's disease, had failed to meet the primary endpoint of slowing cognitive decline. The failure came after more than a decade of investment in the program and was particularly painful because competitor Eisai and Biogen had succeeded in late 2022 with lecanemab (Leqembi), receiving FDA accelerated approval in January 2023 and full approval in July 2023. Roche subsequently discontinued the gantenerumab program in late 2022 and absorbed a charge in its 2022 results. Roche has continued to pursue Alzheimer's through other modalities, including an oral gantenerumab follow-on (trontinemab) and a research partnership with Banner Alzheimer's Institute, but the November 2022 failure left the company without an approved disease-modifying Alzheimer's therapy at a time when the category was expected to generate tens of billions in annual revenue by the late 2020s. The episode reinforced the case that biology in Alzheimer's remains poorly understood and is the principal reason Roche's neuroscience pipeline is now anchored by Ocrevus and Evrysdi (spinal muscular atrophy) rather than by Alzheimer's products.